JP2013506622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013506622A5 JP2013506622A5 JP2012525756A JP2012525756A JP2013506622A5 JP 2013506622 A5 JP2013506622 A5 JP 2013506622A5 JP 2012525756 A JP2012525756 A JP 2012525756A JP 2012525756 A JP2012525756 A JP 2012525756A JP 2013506622 A5 JP2013506622 A5 JP 2013506622A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding portion
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 14
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 14
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 14
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 14
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 230000008685 targeting Effects 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 5
- 150000003384 small molecules Chemical class 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 108091007960 PI3Ks Proteins 0.000 claims 4
- 102000038030 PI3Ks Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 206010069755 K-ras gene mutation Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108020004705 Codon Proteins 0.000 claims 2
- 102000029749 Microtubule Human genes 0.000 claims 2
- 108091022875 Microtubule Proteins 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 210000004688 microtubule Anatomy 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims 1
- 102100030708 GTPase KRas Human genes 0.000 claims 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 1
- 101100086477 Homo sapiens KRAS gene Proteins 0.000 claims 1
- 101100190564 Homo sapiens PIK3CA gene Proteins 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 102100020870 La-related protein 6 Human genes 0.000 claims 1
- 108050008265 La-related protein 6 Proteins 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 229940124647 MEK inhibitor Drugs 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229940123739 Protein kinase B inhibitor Drugs 0.000 claims 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- -1 hormone therapy Substances 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000003197 protein kinase B inhibitor Substances 0.000 claims 1
- 239000000007 protein synthesis inhibitor Substances 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23579909P | 2009-08-21 | 2009-08-21 | |
| US61/235,799 | 2009-08-21 | ||
| PCT/US2010/046364 WO2011022727A2 (en) | 2009-08-21 | 2010-08-23 | Antibodies against the ectodomain of erbb3 and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013506622A JP2013506622A (ja) | 2013-02-28 |
| JP2013506622A5 true JP2013506622A5 (enrdf_load_stackoverflow) | 2013-10-10 |
| JP5752687B2 JP5752687B2 (ja) | 2015-07-22 |
Family
ID=43607614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012525756A Ceased JP5752687B2 (ja) | 2009-08-21 | 2010-08-23 | Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用 |
Country Status (21)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2129396T3 (pl) | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
| EP3351558B1 (en) * | 2009-11-13 | 2020-03-11 | Daiichi Sankyo Europe GmbH | Material and methods for treating or preventing her-3 associated diseases |
| RU2560583C2 (ru) | 2009-12-22 | 2015-08-20 | Рош Гликарт Аг | Антитела к her3 и их применения |
| CN102858335B (zh) | 2010-03-11 | 2015-04-15 | 梅里麦克制药股份有限公司 | Erbb3抑制剂在三阴性乳腺癌和基底样乳腺癌治疗中的用途 |
| CA2795799C (en) | 2010-04-09 | 2018-09-25 | Aveo Pharmaceuticals, Inc. | Anti-erbb3 antibodies |
| NZ607337A (en) | 2010-08-20 | 2015-06-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| IT1402149B1 (it) * | 2010-10-04 | 2013-08-28 | Ist Fisioterap Ospitalroma | Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2. |
| ES2692379T3 (es) | 2010-11-01 | 2018-12-03 | Symphogen A/S | Anticuerpos anti-HER3 y composiciones |
| KR101517320B1 (ko) * | 2011-04-19 | 2015-05-28 | 메리맥 파마슈티컬즈, 인크. | 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체 |
| AU2012274461A1 (en) | 2011-06-20 | 2014-01-16 | Kyowa Hakko Kirin Co., Ltd. | Anti-erbB3 antibody |
| CA2849508C (en) | 2011-09-30 | 2020-12-22 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| CN108753942A (zh) | 2011-10-06 | 2018-11-06 | Aveo制药公司 | 预测肿瘤对抗erbb3抗体的应答 |
| EP2788377B1 (en) * | 2011-11-09 | 2019-01-23 | The UAB Research Foundation | Her3 antibodies and uses thereof |
| TW201328706A (zh) | 2011-12-05 | 2013-07-16 | Novartis Ag | 表皮生長因子受體３（ｈｅｒ３）之抗體 |
| US20150037336A1 (en) * | 2012-02-22 | 2015-02-05 | U3 Pharma Gmbh | Combination of hb-egf binding protein and egfr inhibitor |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| US20160232293A1 (en) * | 2013-10-17 | 2016-08-11 | Sanford-Burnham Medical Research Institute | Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
| CN110642952B (zh) * | 2014-08-14 | 2021-05-25 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
| WO2016038609A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| AU2015313811A1 (en) | 2014-09-08 | 2017-04-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI) |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| MD3365373T2 (ro) | 2015-10-23 | 2021-08-31 | Merus Nv | Molecule de legare care inhibă dezvoltarea cancerului |
| MX2019011660A (es) | 2017-03-31 | 2019-11-18 | Merus Nv | Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1). |
| EA201992522A1 (ru) | 2017-05-17 | 2020-04-22 | Мерус Н.В. | КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
| CA3072267A1 (en) | 2017-08-09 | 2019-02-14 | University Of Saskatchewan | Her3 binding agents and uses thereof |
| EA202090215A1 (ru) | 2017-08-09 | 2020-07-01 | Мерус Н.В. | АНТИТЕЛА, СВЯЗЫВАЮЩИЕ EGFR И cMET |
| GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
| JP2021534811A (ja) * | 2018-06-22 | 2021-12-16 | シーアールディー ファーマシューティカルズ インコーポレイティド | 抗ｈｅｒ３抗体およびその用途 |
| CA3196940A1 (en) * | 2020-10-14 | 2022-04-21 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof |
| CA3199259A1 (en) * | 2020-11-20 | 2022-05-27 | Dale L Ludwig | Her3 radioimmunotherapy for the treatment of solid cancers |
| IL309337A (en) * | 2021-06-15 | 2024-02-01 | Beijing Sinotau Bio Pharmaceuticals Tech Co Ltd | Anti-HER3 antibody, anti-HER3 antibody-drug conjugate and uses thereof |
| WO2023198138A1 (zh) * | 2022-04-13 | 2023-10-19 | 上海翰森生物医药科技有限公司 | 抗体或其抗原结合片段及其医药用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2129396T3 (pl) * | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
-
2010
- 2010-08-23 CA CA2771744A patent/CA2771744A1/en not_active Abandoned
- 2010-08-23 EA EA201200195A patent/EA201200195A1/ru unknown
- 2010-08-23 SG SG2012011664A patent/SG178509A1/en unknown
- 2010-08-23 CN CN2010800477186A patent/CN103002912A/zh active Pending
- 2010-08-23 BR BR112012003809A patent/BR112012003809A2/pt not_active IP Right Cessation
- 2010-08-23 PE PE2012000234A patent/PE20121585A1/es not_active Application Discontinuation
- 2010-08-23 WO PCT/US2010/046364 patent/WO2011022727A2/en active Application Filing
- 2010-08-23 EP EP10810721A patent/EP2467164A2/en not_active Withdrawn
- 2010-08-23 JP JP2012525756A patent/JP5752687B2/ja not_active Ceased
- 2010-08-23 KR KR1020127007280A patent/KR20120059568A/ko not_active Withdrawn
- 2010-08-23 IN IN1518DEN2012 patent/IN2012DN01518A/en unknown
- 2010-08-23 AU AU2010284018A patent/AU2010284018C1/en not_active Ceased
- 2010-08-23 MX MX2012002172A patent/MX336091B/es unknown
-
2012
- 2012-02-09 TN TNP2012000057A patent/TN2012000057A1/en unknown
- 2012-02-14 IL IL218097A patent/IL218097A0/en unknown
- 2012-02-15 NI NI201200027A patent/NI201200027A/es unknown
- 2012-02-17 ZA ZA2012/01195A patent/ZA201201195B/en unknown
- 2012-02-20 DO DO2012000044A patent/DOP2012000044A/es unknown
- 2012-03-05 CR CR20120108A patent/CR20120108A/es unknown
- 2012-03-12 MA MA34684A patent/MA33582B1/fr unknown
- 2012-03-21 EC ECSP12011740 patent/ECSP12011740A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013506622A5 (enrdf_load_stackoverflow) | ||
| KR102068600B1 (ko) | Pdl-1 항체, 그 약학적 조성물 및 그 용도 | |
| US10058610B2 (en) | Methods for treating cancer by administering humanized pan-HER antibody compositions | |
| CN102421802B (zh) | 人源化的axl抗体 | |
| EP3470435B1 (en) | Antibody that binds erbb-2 and erbb-3 | |
| JP2020520370A (ja) | 抗ＳＩＲＰα抗体 | |
| JP2017149720A5 (enrdf_load_stackoverflow) | ||
| TW201542594A (zh) | 雙特異性ｈｅｒ２抗體 | |
| JP2010518820A5 (enrdf_load_stackoverflow) | ||
| BR112015011518B1 (pt) | Anticorpo heterodimérico, ácido nucleico e vetor | |
| JP2014522850A5 (enrdf_load_stackoverflow) | ||
| JP2020514277A5 (enrdf_load_stackoverflow) | ||
| US20240294622A1 (en) | Novel anti-gremlin1 antibodies | |
| US20250136720A1 (en) | Bispecific and tetravalent cd137 and fap molecules for the treatment of cancer | |
| JP2020513759A5 (enrdf_load_stackoverflow) | ||
| JP7065935B2 (ja) | 抗ｌｙ６ｇ６ｄ抗体及び使用方法 | |
| EP3765156A1 (en) | De-immunised anti-erbb3 antibodies | |
| Amiri et al. | Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition | |
| US20230357391A1 (en) | Cd47 binding agents and uses thereof | |
| CN118139888A (zh) | 抗cldn18.2抗体及其用途 | |
| CN118076387A (zh) | 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法 | |
| WO2023227115A1 (en) | A method of treating solid tumor | |
| JPWO2021173832A5 (enrdf_load_stackoverflow) | ||
| HK40051621A (en) | Antibody that binds erbb-2 and erbb-3 | |
| HK40006122B (en) | Antibody that binds erbb-2 and erbb-3 |